8-K: Pluri Secures $2.5M Private Placement, Appoints New Board Leadership

Pluri Inc. announced a $2.5 million private placement with Chutzpah Holdings LP, led by director Alexandre Weinstein, alongside key board appointments and RSU grants for executive and board compensation.

Summary

• Pluri Inc. entered into a Securities Purchase Agreement with Chutzpah Holdings LP for a private placement offering.
• The offering includes 625,000 common shares and warrants to purchase up to an additional 625,000 common shares.
• The combined purchase price for each common share and common warrant is $4.00.
• The warrants are exercisable immediately at an exercise price of $4.25 per share and expire on June 30, 2026.
• Gross proceeds from the offering are expected to be approximately $2.5 million, intended for working capital and general corporate purposes.
• The offering is expected to close on or about December 15, 2025, subject to customary closing conditions.
• The securities are exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S.
• Mr. Alexandre Weinstein, a non-U.S. investor and existing shareholder and director, beneficially owns Chutzpah Holdings LP.
• Mr. Weinstein was appointed Chairman of the Board, and Mr. Zami Aberman was appointed Vice Chairman of the Board, effective December 4, 2025.
• Mr. Aberman's consultancy agreement with the Company will terminate effective January 4, 2026.
• The board granted 10,248 restricted stock units (RSUs) to the CEO and CFO, and 2,885 RSUs to Board members, in lieu of cash compensation.
• These RSUs vest in equal monthly installments over three months, supporting cost-management and aligning incentives with long-term performance.

Sentiment

Score: 6

Explanation: The filing indicates a necessary capital infusion and strategic board appointments, along with cost-saving compensation measures. While dilutive, the capital provides operational runway, and the involvement of an existing director in the private placement can be seen as a vote of confidence. The warrant exercise price being above the purchase price is a positive. Overall, it's a constructive, albeit standard, set of corporate actions.

Positives

• Secured approximately $2.5 million in gross proceeds, providing additional working capital and funds for general corporate purposes.
• The private placement demonstrates continued investment from an existing director and significant shareholder, indicating confidence in the company's future.
• Warrants have an exercise price of $4.25, which is above the combined purchase price of $4.00, potentially providing future capital if exercised.
• Appointment of Mr. Alexandre Weinstein as Chairman and Mr. Zami Aberman as Vice Chairman strengthens board leadership.
• Granting RSUs in lieu of cash compensation for executives and board members supports cost-management initiatives and aligns leadership incentives with long-term performance.

Negatives

• The issuance of common shares and warrants will result in dilution for existing shareholders.
• The private placement is with a related party (a director's beneficially owned entity), which, while a vote of confidence, can sometimes raise questions about arm's-length transactions.

Risks

• The conditions to the closing of the offering may not be met, potentially delaying or preventing the capital infusion.
• Changes in technology and market requirements could adversely affect the company's business.
• Delays or obstacles in launching and/or successfully completing clinical trials, if necessary, could impact product development.
• The company's products may not be approved by regulatory agencies, hindering commercialization.
• The company's technology may not be validated as it progresses, or its methods may not be accepted by the scientific community.
• Inability to retain or attract key employees whose knowledge is essential to product development could impede progress.
• Unforeseen scientific difficulties may develop with the company's processes.
• The company's products may wind up being more expensive than anticipated, affecting market competitiveness.
• Results in the laboratory may not translate to equally good results in real clinical settings.
• The company's patents may not be sufficient to protect its intellectual property.
• The company's products may harm recipients or consumers, leading to liabilities.
• Changes in legislation could have an adverse impact on the company's operations.
• Inability to timely develop and introduce new technologies, products, and applications could result in missed opportunities.
• Loss of market share and pressure on pricing resulting from competition could negatively affect financial performance.

Future Outlook

The company expects the private placement offering to close on or about December 15, 2025, subject to customary closing conditions. The proceeds are intended for working capital and general corporate purposes. The company also anticipates continued compliance with its cost-management initiatives through equity-based compensation for leadership.

Management Comments

• The RSU grants were made to support the Company's cost-management initiatives and to align leadership incentives with long-term performance objectives.

Industry Context

This private placement and board restructuring occur within a broader industry context where biotech and life sciences companies often rely on capital raises to fund research, development, and operational expenses. The use of equity compensation in lieu of cash is a common strategy for early-stage or growth companies to conserve cash while retaining and incentivizing key personnel. The involvement of an existing director in the capital raise can signal internal confidence, which may be viewed positively by the market, especially in sectors with high capital requirements and long development cycles.

Comparison to Industry Standards

• The combined purchase price of $4.00 for a share and a warrant, with a warrant exercise price of $4.25, is a common structure in private placements, often designed to provide immediate capital while offering future upside potential to investors if the stock price appreciates.
• The 35% beneficial ownership limitation on warrants is a standard anti-dilution and control protection mechanism, preventing any single holder from accumulating too large a stake through warrant exercise without further disclosure or regulatory review.
• Granting Restricted Stock Units (RSUs) to executives and board members in lieu of cash compensation is a widely adopted practice in the biotech and technology sectors, particularly for companies focused on cash conservation and aligning management's interests with long-term shareholder value. This practice is consistent with industry benchmarks for incentivizing leadership in capital-intensive industries.
• The appointment of an existing director (Mr. Weinstein) as Chairman and another as Vice Chairman is a common internal governance adjustment, often aimed at leveraging existing institutional knowledge and relationships. This is not unusual compared to similar-sized companies in the biotech space.

Management Changes

Corporate Governance

Related Party Transactions

• The private placement is with Chutzpah Holdings LP, which is beneficially owned by Mr. Alexandre Weinstein, an existing shareholder and director of Pluri Inc.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares and warrants, but benefit from the capital infusion for company operations and potential long-term growth. The appointment of an existing director as Chairman may signal stability.
• Executives and Board Members: Receive equity-based compensation (RSUs) in lieu of cash, aligning their interests with long-term company performance and supporting cash conservation.
• Creditors: The capital raise strengthens the company's financial position, potentially improving its ability to meet obligations.

Next Steps

• The private placement offering is expected to close on or about December 15, 2025, subject to satisfaction of customary closing conditions.
• Mr. Aberman's consultancy agreement with the Company will be terminated effective January 4, 2026.
• The company will use the proceeds from the offering for working capital and general corporate purposes.
• The company will file additional listing applications and/or notices with Nasdaq and the Tel Aviv Stock Exchange for the listing of the Common Shares and Warrant Shares.

Key Dates

Recommendation

The private placement provides a necessary capital injection for working capital and general corporate purposes, which is a positive for operational stability. The involvement of an existing director in the capital raise, while dilutive, can be interpreted as a vote of confidence. The RSU grants in lieu of cash demonstrate a commitment to cost management. However, the dilution from the offering and warrants, combined with the inherent risks of the biotech sector (as outlined in the safe harbor statement), suggest a 'hold' position. Investors should monitor the effective deployment of the raised capital and the impact of the new board leadership on strategic direction and financial performance.

Keywords

Private Placement, Warrants, Capital Raise, Equity Financing, Corporate Governance, Board Appointments, Restricted Stock Units, SEC Filing, PLUR, Chutzpah Holdings LP